- Home
- GMAB vs SUZ Comparison
GMAB vs SUZ Comparison
Compare GMAB & SUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- SUZ
- Stock Information
- Founded
- GMAB 1999
- SUZ 1924
- Country
- GMAB Denmark
- SUZ Brazil
- Employees
- GMAB N/A
- SUZ N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- SUZ Paper
- Sector
- GMAB Health Care
- SUZ Basic Materials
- Exchange
- GMAB Nasdaq
- SUZ Nasdaq
- Market Cap
- GMAB 13.7B
- SUZ 11.6B
- IPO Year
- GMAB N/A
- SUZ N/A
- Fundamental
- Price
- GMAB $20.30
- SUZ $9.57
- Analyst Decision
- GMAB Buy
- SUZ
- Analyst Count
- GMAB 8
- SUZ 0
- Target Price
- GMAB $37.60
- SUZ N/A
- AVG Volume (30 Days)
- GMAB 1.5M
- SUZ 1.8M
- Earning Date
- GMAB 08-07-2025
- SUZ 08-07-2025
- Dividend Yield
- GMAB N/A
- SUZ 2.77%
- EPS Growth
- GMAB 276.80
- SUZ N/A
- EPS
- GMAB 18.36
- SUZ N/A
- Revenue
- GMAB $3,230,902,140.00
- SUZ $8,633,051,515.00
- Revenue This Year
- GMAB $747.74
- SUZ $17.17
- Revenue Next Year
- GMAB $14.81
- SUZ $9.27
- P/E Ratio
- GMAB $11.07
- SUZ N/A
- Revenue Growth
- GMAB 25.43
- SUZ 30.47
- 52 Week Low
- GMAB $17.24
- SUZ $8.41
- 52 Week High
- GMAB $28.56
- SUZ $10.98
- Technical
- Relative Strength Index (RSI)
- GMAB 39.68
- SUZ 56.19
- Support Level
- GMAB $20.39
- SUZ $9.24
- Resistance Level
- GMAB $21.08
- SUZ $9.44
- Average True Range (ATR)
- GMAB 0.35
- SUZ 0.16
- MACD
- GMAB -0.20
- SUZ -0.01
- Stochastic Oscillator
- GMAB 2.63
- SUZ 51.45
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.